Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities |
| |
| Affiliation: | 1. Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;2. Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY;3. James J. Peters VA Medical Center, Bronx, NY;4. Columbia University Irving Medical Center, New York, NY;5. Division of Pulmonary and Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;1. Department of Surgery, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands;2. Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands;3. Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands;4. Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands;1. Monter Cancer Center, Hematology/Medical Oncology, Northwell Health Cancer Institute, New Hyde Park, New York;2. Department of Medicine, Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachussets, USA.;1. Research Unit @CoeurLab, Centre de Recherche du Centre Hospitalier de l''Université de Montréal (CRCHUM);2. Hemato-Oncology division, Département d''Hématologie-Médecine Transfusionnelle du Centre Hospitalier de l''Université de Montréal (CHUM);3. Cardiology division, Département de Médecine du Centre Hospitalier de l''Université de Montréal (CHUM);1. Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.;2. Key Laboratory of Early Prevention and Treatment for Regional High‐Incidence Tumor, Guangxi Medical University, Ministry of Education, Nanning, Guangxi, China.;3. Department of Oncology, Affiliated Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, China.;1. Department of Medicine, Staten Island University Hospital, Staten Island, New York;2. Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon;3. Hammoud Hospital University Medical Center, Saida, Lebanon |
| |
| Abstract: | Veterans with locoregional non-small cell lung cancer (NSCLC) may benefit from adjuvant chemotherapy. However, comorbidities and other factors may impact the harms and benefits of this treatment. Here, we identified the optimal indications for adjuvant chemotherapy in Veterans with NSCLC, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), and/or coronary artery disease (CAD). We used data from randomized controlled trials (RCTs) and Veterans Administration (VA) databases to enhance a simulation model. Then, we conducted in-silico RCTs comparing adjuvant chemotherapy vs observation among Veterans with stage II-IIIA NSCLC. Among Veterans without COPD or CKD, adjuvant chemotherapy was the optimal strategy regardless of the presence or absence of CAD except for patients >70 years with squamous cell carcinoma. Conversely, most veterans without COPD but with CKD were optimally managed with observation. Veterans with COPD but without CKD, benefited from adjuvant chemotherapy if they were ≤70 years with stage II-IIIA adenocarcinoma or <60 years with stage II-IIIA squamous cell carcinoma. Adjuvant chemotherapy was only beneficial for Veterans with both COPD and CKD among stage II-IIIA adenocarcinoma <60 years of age. Veterans with stages II-IIIA squamous cell carcinoma, COPD, and CKD were optimally managed with observation. Many Veterans with comorbidities are optimally managed with observation post-surgical resection. However, we also identified several groups of Veterans whom the benefits of adjuvant chemotherapy outweighed the risks of early toxicity. Our findings could inform patient-provider discussions and potentially reduce physicians’ uncertainty about the role of adjuvant chemotherapy in this population. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
